- Home
- REBN vs AIMD Comparison
REBN vs AIMD Comparison
Compare REBN & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REBN | AIMD |
|---|---|---|
| Founded | 2015 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 16.9M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | REBN | AIMD |
|---|---|---|
| Price | $1.65 | $2.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 62.8K | 35.6K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,663,303.00 | $113,037.00 |
| Revenue This Year | $335.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 21.09 | ★ 178.19 |
| 52 Week Low | $1.06 | $1.78 |
| 52 Week High | $8.30 | $5.00 |
Technical Indicators
Market Signals| Indicator | REBN | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 43.87 |
| Support Level | $1.62 | $2.12 |
| Resistance Level | $1.80 | $2.56 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 18.84 | 62.82 |
Price Performance
Historical ComparisonAbout REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.